Navigation Links
Cardica and Cook Sign Agreement to Expand Cook Vascular Closure Device Product Family
Date:9/20/2007

niques. In approximately 45 percent of these cases, a closure device was used, and that number is steadily increasing. The worldwide market for femoral artery closure devices alone is estimated to be over $750 million by 2008.

The potential advantages of the closure devices developed by Cardica and Cook include a simple user interface, the ability to place it through the same introducer sheath used for the interventional procedure for greater convenience and speed, scalability, and lower cost of goods.

About Cook Medical

Cook Medical was the first company to introduce interventional devices in the United States. Today, the company integrates device design, biopharma, gene and cell therapy and biotech to enhance patient safety and improve clinical outcomes in the fields of aortic intervention; cardiology; critical care medicine; gastroenterology; radiology, peripheral vascular, bone access and oncology; surgery and soft tissue repair; urology; and assisted reproductive technology, gynecology and high-risk obstetrics. Cook won the prestigious Medical Device Manufacturer of the Year Award for 2006 from Medical Device & Diagnostic Industry magazine. For more information, visit http://www.cookmedical.com.

About Cardica, Inc.

Cardica designs and manufactures automated anastomosis systems for coronary artery bypass graft (CABG) surgery. By replacing hand-sewn sutures with easy-to-use automated systems, Cardica provides cardiovascular surgeons with the ability to perform rapid, reliable and consistently reproducible anastomoses, or connections of blood vessels, often considered the most critical aspect of the CABG procedure.

Cardica's C-Port(R) Distal Anastomosis Systems are marketed in Europe and the United States. The PAS-Port(R) Proximal Anastomosis System is marketed in Europe and Japan and is being evaluated in a pivotal trial in the United States and Europe. Cardica also is deve
'/>"/>

SOURCE Cardica, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. WARF enters licensing agreements for stem cell products
2. Quick peeks, Clawback Agreements, and the rules of electronic discovery
3. Virent enters agreement with Shell Oil unit to make hydrogen with biomass
4. WARF expands license agreement with Advanced Cell Technology
5. Lucigen Corp. enters global licensing agreement
6. GE Healthcare enters agreement with Canadian health authority
7. New angel capital centered on GenTel agreement with big pharma
8. Mirus Bio, Pfizer enter multimillion-dollar research agreement
9. Prodesse enters patent agreement with Roche
10. TeraMedica signs agreement with ThedaCare
11. CATI signs agreement for food processing technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2009)TUSTIN, Calif., Dec. 2 Peregrine Pharmaceuticals, Inc. (Nasdaq: PPHM ) today reported completion of patient enrollment in a dose confirmation and dosimetry trial of Cotara® in patients with rel
(Date:12/2/2009)LIBREVILLE, Gabon, December 2 , - "Bolstering Biodiversity in Africa: Everyone,s Problem and Heritage" , Coinciding with the International Year of Biodiversity, 2-3 June 2010 the,Gabonese Rep
(Date:12/2/2009)CAMBRIDGE, Mass., Dec. 2 TechConnect World, an event bringing together the leaders in technology development and product integration in cleantech, nanotech, biotech and MEMS, announced the December 1
(Date:12/2/2009)SINGAPORE, Dec. 2 S*BIO Pte Ltd today announced data presentations on its novel oral JAK2 inhibitor, SB1518, at The American Society of Hematology 51st Annual Meeting and Exposition in New Orleans. ,
Breaking Biology Technology:Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 2Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 3Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 4Peregrine Completes Patient Enrollment in Cotara(R) Dose Confirmation and Dosimetry Brain Cancer Trial 5Libreville International Conference 2-3 June 2010 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 2Deadline Approaching for Largest Commercialization Event for Nanotech & Clean Technologies 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 2S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 3S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 4S*BIO Novel Oral JAK2 Inhibitor SB1518 Demonstrates Safety and Tolerability in Phase 1 Studies for the Treatment of Myeloproliferative and Other Hematological Disorders 5
... PARK, Calif., May 27 ForteBio(R), Inc., a leadin...es the development of biotherapeutic and pharmaceu...ed two new assay modules - for high-sensitivity pr...ively - for use on the company,s Octet(R) instrume...a software upgrades and will enable, for the first...
...LL, WA and VANCOUVER, May 27 /PRNewswire-FirstCall...I ) announced today that the Company will hold a l...ade at an OncoGenex hosted reception during the 20...eting (ASCO) on Saturday, May 30, 2009. The webcas...ion, OncoGenex management and guest speakers will ...
...arch has shown that certain marginalized groups i... minorities such as African Americans and Latinos ...l disasters, suffering disproportionate impoverish...udy by UCLA researchers and colleagues has found t... fears and make more behavioral changes based on t...
Other Biology Technology:ForteBio Launches New Assay Capabilities for High-Sensitivity Protein Quantitation and Fragment Screening on Its Octet(R) Platform 2OncoGenex Pharmaceuticals to Webcast ASCO Reception on May 30, 2009 2Disabled and other vulnerable groups more susceptible to terrorism fears 2
(Date:12/4/2009)This release is available in German . , A new study of the Max Planck Institute for Biology of Ageing could help to understand the positive effect of dietary restriction on healthy ageing. Previou
(Date:12/3/2009)Our ability to learn new information and adapt to changes in our daily environment, as well as to retain lifelong memories, appears to lie in the minute junctions where nerve cells communicate, accord
(Date:12/3/2009)ALBUQUERQUE, N.M. Most scientists believe that staph infections are caused by many bacterial cells that signal each other to emit toxins. The signaling process is called quorum sensing because many b
Breaking Biology News(10 mins):How nutrition affects healthy aging 2Lifelong memories linked to stable nerve connections 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 2Stopping MRSA before it becomes dangerous is possible, Sandia/UNM researchers find 3Elpac Power System Extends Energy Star Portfolio with 65 Watt External Power Supply 54525 1Elpac Power System Extends Energy Star Portfolio with 65 Watt External Power Supply 54525 2Miami Health Insurance Outlook and Update 54523 1Miami Health Insurance Outlook and Update 54523 2Miami Health Insurance Outlook and Update 54523 3Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 1Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 2Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 3Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 4Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 5Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 6Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 7Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 8Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 9Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 10Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 11Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 12Transcept Pharmaceuticals Reports Second Quarter 2009 Financial Results 54522 13
...ss announces the latest edition of an essential ...pidly changing fields of clinical medicine. Coveri...nosis, treatment, and prevention, Clinical Virolo...ls about all the medically relevant aspects of thi...tly one of the most dynamic areas of clinical medi...
...helle, NY, March 17, 2009While the Bernard Madoff ...undation, a major benefactor for life science rese...from the scandal as a minor consequence in the lar... & Biotechnology News (GEN). They look at the Mad... global financial environment that has been rocked...
... human papilloma virus (HPV)-infections can lead t...-stage to cervical cancer. Surgical treatment of t... birth in subsequent pregnancies. As the HPV-vacci...ay therefore reduce the number of preterm births. ...of HPV-vaccination. , Cervical cancer developmen...
Other Biology News:New edition available for essential virology reference 2GEN reports on Madoff scandal's impact on the life sciences 2HPV vaccine may prevent preterm births 2
...be gel adaptors, 24 glass tubes (1.5 mm ID, 180 mm... II xi cell and PROTEAN II XL wide-format cell off...ions,* including SDS-PAGE, first- and second-dimen... gradient PAGE as well as high-resolution agarose ...
SVT3-2 Diverter Valve from Bio-Rad
PROTEAN II XL Cell, wide format from Bio-Rad
PROTEAN II xi Cell, 20 cm, without spacers and combs from Bio-Rad
Biology Products: